Speaking before the House Energy and Commerce Committee of the U.S. House of Representatives on the implementation of the 21st Century Cures Act, Norman (Ned) Sharpless, M.D., Director of the National Cancer Institute (NCI) was asked by Missouri Congressman Billy Long, “Can you tell us about the most exciting thing that is being supported in the Cancer Moonshot?”
Sharpless focused his answer on the NCI’s Rare Tumor Initiative and the clinical trial presented in June at the ASCO Conference by Andrea Gross, MD of the NCI about the selumetinib (MEK inhibitor) clinical trial treating inoperable NF1 plexiform neurofibromas.
International collaborative research led by Ludwine Messiaen, PhD, shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis type 1, or NF1, the mutation does cause complications. CTF has invested in Dr. Messiaen’s promising work by providing the Isaac and Sadie Fuchs Genotype-Phenotype Grant.
Ask Kate! is a new weekly YouTube series to answer your questions about neurofibromatosis! Kate Kelts, RN, BSN is the Patient Support Coordinator for the Children's Tumor Foundation, and each week she will answer questions submitted directly by viewers. If you have a question you'd like to see Kate answer, you can include it in the YouTube comments of the latest video, or email Kate at KKelts@ctf.org.
Click here to subscribe and click the bell to receive alerts when new videos are posted. Click "Read More" to view the first two videos in this exciting new YouTube series!
Honorees include philanthropist Carol Harrison Kalagher, NIH Director Francis S. Collins, and NF Ambassador McKinnon Galloway. Festivities to take place at the renowned American Museum of Natural History in NYC on October 22.
The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will open for applications for its 2019 Pershing Square Sohn Prize for Young Investigators in Cancer Research on October 1st, 2018. At least six New York City-area-based scientists will each be awarded $200,000/year – for up to three years – to empower them to pursue groundbreaking research.